Genomic Health, Inc. (GHDX) Shares Bought by Nordea Investment Management AB

Nordea Investment Management AB lifted its holdings in shares of Genomic Health, Inc. (NASDAQ:GHDX) by 18.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 68,812 shares of the medical research company’s stock after buying an additional 10,787 shares during the period. Nordea Investment Management AB owned approximately 0.20% of Genomic Health worth $2,208,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Eagle Asset Management Inc. boosted its stake in shares of Genomic Health by 18.4% during the second quarter. Eagle Asset Management Inc. now owns 379,473 shares of the medical research company’s stock worth $12,351,000 after buying an additional 58,920 shares during the period. Renaissance Technologies LLC boosted its stake in shares of Genomic Health by 10.9% during the second quarter. Renaissance Technologies LLC now owns 813,300 shares of the medical research company’s stock worth $26,473,000 after buying an additional 80,100 shares during the period. Goldman Sachs Group Inc. boosted its stake in shares of Genomic Health by 26.1% during the second quarter. Goldman Sachs Group Inc. now owns 370,806 shares of the medical research company’s stock worth $12,070,000 after buying an additional 76,758 shares during the period. FMR LLC boosted its stake in shares of Genomic Health by 3.1% during the second quarter. FMR LLC now owns 253,948 shares of the medical research company’s stock worth $8,266,000 after buying an additional 7,600 shares during the period. Finally, Vanguard Group Inc. boosted its stake in shares of Genomic Health by 6.8% during the second quarter. Vanguard Group Inc. now owns 1,670,622 shares of the medical research company’s stock worth $54,379,000 after buying an additional 106,452 shares during the period. Institutional investors and hedge funds own 89.61% of the company’s stock.

In other Genomic Health news, insider Phillip G. Febbo sold 5,334 shares of the stock in a transaction dated Tuesday, December 19th. The shares were sold at an average price of $36.99, for a total value of $197,304.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO G Bradley Cole sold 5,000 shares of the stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $29.94, for a total transaction of $149,700.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 62,713 shares of company stock valued at $2,037,926. 46.20% of the stock is currently owned by corporate insiders.

Shares of Genomic Health, Inc. (GHDX) traded down $0.87 during trading on Friday, reaching $34.20. 104,272 shares of the company’s stock were exchanged, compared to its average volume of 234,555. Genomic Health, Inc. has a 12 month low of $26.37 and a 12 month high of $37.50. The stock has a market capitalization of $1,219.92, a PE ratio of -285.00 and a beta of 0.66.

A number of equities research analysts recently commented on the stock. Canaccord Genuity restated a “buy” rating and issued a $35.00 price objective on shares of Genomic Health in a research report on Wednesday, September 27th. ValuEngine downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. JPMorgan Chase & Co. downgraded shares of Genomic Health from a “neutral” rating to an “underweight” rating and set a $25.00 price objective for the company. in a research report on Wednesday, December 13th. BidaskClub upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Tuesday, December 19th. Finally, William Blair downgraded shares of Genomic Health from an “outperform” rating to a “market perform” rating in a research report on Wednesday, December 20th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $31.57.

COPYRIGHT VIOLATION WARNING: “Genomic Health, Inc. (GHDX) Shares Bought by Nordea Investment Management AB” was published by Week Herald and is the sole property of of Week Herald. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://weekherald.com/2017/12/30/nordea-investment-management-ab-buys-10787-shares-of-genomic-health-inc-ghdx.html.

Genomic Health Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply